Does Utah Medicaid cover GLP-1s for weight loss?

Utah Medicaid does not cover GLP-1s prescribed for weight loss. Coverage for type 2 diabetes, for Wegovy's cardiovascular indication and for Zepbound in moderate to severe sleep apnea is required of every state program regardless. So the practical question at a denial is rarely "does my state cover it" but "which indication am I being prescribed this under". For renewal: Weight-loss reauthorization was open only to somebody whose approval was already active between 1 July 2025 and 30 June 2026, and ran no later than 30 June 2026. On the other indications: Wegovy for cardiovascular risk renews for 12 months on 5% weight loss held from week 20; Zepbound for sleep apnea on a 20% fall in the apnea-hypopnea index; Wegovy for MASH on documented clinical response. Where the answer is no, the cheapest verified cash route on this site is $129 a month (compounded, not FDA approved; FDA warning letter). Last checked 2026-09-13.

What Utah changed, and when

2026-07-01 — The weight-loss pilot lapsed: Utah's own prior-authorization form caps every obesity authorization at 30 June 2026 and no longer has an initial-approval route for obesity the document that says so

What Utah will approve, and on what

What it takes: For the indications Utah still covers: Wegovy for a prior major adverse cardiovascular event needs a BMI of 27 or more with a documented MI, stroke or symptomatic peripheral arterial disease and guideline-directed secondary prevention; Zepbound for sleep apnea needs a BMI of 30 or more, an apnea-hypopnea index of 15 or higher on an attended study, a sleep specialist and 70% adherence to PAP; Wegovy for MASH needs stage F2 to F3 fibrosis confirmed two ways and a liver specialist. All of them require an exercise program and a calorie-restricted diet, no other GLP-1, GIP or DPP-4 agent, and no personal or family history of medullary thyroid carcinoma or MEN 2.
To keep it: Weight-loss reauthorization was open only to somebody whose approval was already active between 1 July 2025 and 30 June 2026, and ran no later than 30 June 2026. On the other indications: Wegovy for cardiovascular risk renews for 12 months on 5% weight loss held from week 20; Zepbound for sleep apnea on a 20% fall in the apnea-hypopnea index; Wegovy for MASH on documented clinical response.

Utah's weight-loss coverage was a legislative pilot, and it ended on 30 June 2026: its own prior-authorization form says on every page that mentions obesity that authorizations run 'up to and no later than 6/30/2026'. Under the pilot, adults needed a BMI of 30 or more, or 27 to 29.9 with a weight-related comorbidity, and 12–17 year olds the 95th percentile for age and sex. The version last updated 1 June 2026 no longer has an initial-approval route for obesity at all. The state's own copy would not open for us on 5 September 2026, so it was read from the Internet Archive's 17 July 2026 capture. Utah's live prior-authorization library lists no weight-loss criteria document; the only GLP-1 entry on it is titled 'GLP-1 Medications for Weight-related Comorbidities'.

Both tools fill from these criteria rather than from a template — a prior authorization for Utah, or a letter appealing a denial. If the plan is not Medicaid, the 9 insurer and program pages cover a different set of rules.

Whatever Utah decides about obesity, federal law still makes it cover a GLP-1 prescribed for type 2 diabetes, Wegovy for cardiovascular risk reduction and Zepbound for obstructive sleep apnea — the exclusion is written against the use, not the drug. Which approval a weight-loss exclusion cannot reach, and what each label says.

If you end up paying cash

The cheapest verified GLP-1 routes — what you pay per month once titrated, not an introductory rate:

Strut Health$129/moverified 2026-09-22compounded, not FDA approvedFDA warning letter
Noom Med$249/moverified 2026-09-22compounded, not FDA approved
Found$289/moverified 2026-09-22compounded, not FDA approved

Go to Strut Health, the cheapest verified route ↗

Every verified price, ranked and segmented →

Cheaper still, and a different class: Qsymia (phentermine/topiramate) at $75/mo — about 9.8% mean weight loss in its trial, against roughly 15 to 21% for the GLP-1s above. It is a real option and it is not a substitute.

The manufacturer programs cut the first fills further, and each one's catch is printed with it. Write the appeal first if you were refused — it costs nothing and the criteria above are what it has to answer.

Other states with criteria of their own

Source: Utah Medicaid pharmacy prior authorization request form: GLP-1 medications for weight-related comorbidities, last updated 1 June 2026 (read via the Internet Archive) , effective 2026-06-01. Read on 2026-09-13. Fee-for-service rules; a managed-care plan in Utah can publish its own formulary and step edits. This is a record of what the payer publishes, not medical or legal advice.